{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T02:14:40Z","timestamp":1774404880809,"version":"3.50.1"},"reference-count":78,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2018,2,26]],"date-time":"2018-02-26T00:00:00Z","timestamp":1519603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007637","name":"Colciencias","doi-asserted-by":"publisher","award":["123071150104"],"award-info":[{"award-number":["123071150104"]}],"id":[{"id":"10.13039\/100007637","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Sensors"],"abstract":"<jats:p>This study describes the development of an immunosensory label-free quantification methodology based on surface plasmon resonance (SPR) and its applicability in measuring\/evaluating therapeutic drug monitoring (TDM) of anti-TNF-\u03b1 monoclonal antibody (adalimumab) in rheumatoid arthritis (RA) patients. The experimental parameters evaluated in this study were immobilising ligands by pre-concentration assays, sensor surface regeneration, ascertaining the method\u2019s sensitivity and correlating the results from quantifying plasma samples by ELISA immunoassay. The results showed that TNF-\u03b1 quantification values (in RU) were significantly different when comparing patients (~50\u2013250 RU) to controls (~10\u201320 RU). Likewise, there was 0.97 correlation for patients and 0.91 for healthy volunteers using SPR and ELISA comparison methodologies. SPR immunosensory detection provided a precise, sensitive strategy, along with real-time determination, for quantifying adalimumab, having great potential for clinical routine regarding TDM.<\/jats:p>","DOI":"10.3390\/s18030691","type":"journal-article","created":{"date-parts":[[2018,2,27]],"date-time":"2018-02-27T03:36:12Z","timestamp":1519702572000},"page":"691","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Label-Free Quantification of Anti-TNF-\u03b1 in Patients Treated with Adalimumab Using an Optical Biosensor"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0243-2299","authenticated-orcid":false,"given":"Rosa","family":"Bustos","sequence":"first","affiliation":[{"name":"Evidence-Based Therapeutics Group, Clinical Pharmacology, Universidad de La Sabana, 140013 Ch\u00eda, Colombia"}]},{"given":"Carlos","family":"Zapata","sequence":"additional","affiliation":[{"name":"Evidence-Based Therapeutics Group, Clinical Pharmacology, Universidad de La Sabana, 140013 Ch\u00eda, Colombia"}]},{"given":"Efra\u00edn","family":"Esteban","sequence":"additional","affiliation":[{"name":"Evidence-Based Therapeutics Group, Clinical Pharmacology, Universidad de La Sabana, 140013 Ch\u00eda, Colombia"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1136-848X","authenticated-orcid":false,"given":"Julio-C\u00e9sar","family":"Garc\u00eda","sequence":"additional","affiliation":[{"name":"Evidence-Based Therapeutics Group, Clinical Pharmacology, Universidad de La Sabana, 140013 Ch\u00eda, Colombia"}]},{"given":"Edwin","family":"J\u00e1uregui","sequence":"additional","affiliation":[{"name":"Riesgo de Fractura S.A.-CAYRE, 110221 Bogot\u00e1, Colombia"}]},{"given":"Diego","family":"Jaimes","sequence":"additional","affiliation":[{"name":"Evidence-Based Therapeutics Group, Clinical Pharmacology, Universidad de La Sabana, 140013 Ch\u00eda, Colombia"}]}],"member":"1968","published-online":{"date-parts":[[2018,2,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.biologicals.2014.05.005","article-title":"The challenge of indication extrapolation for infliximab biosimilars","volume":"42","author":"Feagan","year":"2014","journal-title":"Biologicals"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Bendtzen, K., and Svenson, M. (2011). Enzyme Immunoassays and Radioimmunoassays for Quantification of Anti-TNF Biopharmaceuticals and Anti-Drug Antibodies. Detection and Quantification of Antibodies to Biopharmaceuticals, John Wiley & Sons.","DOI":"10.1002\/9781118075685.ch5"},{"key":"ref_3","unstructured":"European Medicines Agency (2017, November 03). Guideline on Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins. Available online: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2015\/10\/WC500194507.pdf."},{"key":"ref_4","unstructured":"US Food and Drug Administration (2017). Biosimilars Guidances."},{"key":"ref_5","unstructured":"WHO (World Health Organization) (2018, February 21). Guidelines of Evaluation for Similar Biotherapeutics Products (SBPs). Available online: http:\/\/www.who.int\/biologicals\/areas\/biological_therapeutics\/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1517\/14712598.5.1.S37","article-title":"Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins","volume":"5","author":"Ternant","year":"2005","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/intimm\/dxx055","article-title":"Targeted antibody therapy and relevant novel biomarkers for precision medicine for rheumatoid arthritis","volume":"29","author":"Kaneko","year":"2017","journal-title":"Int. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/j.clinthera.2017.06.007","article-title":"Costs of Providing Infusion Therapy for Rheumatoid Arthritis in a Hospital-based Infusion Center Setting","volume":"39","author":"Schmier","year":"2017","journal-title":"Clin. Ther."},{"key":"ref_9","first-page":"359","article-title":"Cost Management through Care Management, Part 2: The Importance of Managing Specialty Drug Utilization in the Medical Benefit","volume":"5","author":"Einodshofer","year":"2012","journal-title":"Am. Health Drug Benefits"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1007\/s12325-016-0372-z","article-title":"Efficacy and Treatment Costs of Monotherapy with bDMARDs in the Treatment of Rheumatoid Arthritis in Patients Intolerant to or Inappropriate to Continue Treatment with Methotrexate","volume":"33","author":"Batticciotto","year":"2016","journal-title":"Adv. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1080\/17425255.2017.1377180","article-title":"Primary and secondary nonresponse to infliximab: Mechanisms and countermeasures","volume":"13","author":"Wong","year":"2017","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/clpt.2011.328","article-title":"Anti-TNF monoclonal antibodies in inflammatory bowel disease: Pharmacokinetics-based dosing paradigms","volume":"91","author":"Ordas","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ddtec.2016.09.004","article-title":"Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies","volume":"21\u201322","author":"Kamath","year":"2016","journal-title":"Drug Discov. Today Technol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1517\/17425255.2012.643868","article-title":"Monoclonal antibodies: What are the pharmacokinetic and pharmacodynamic considerations for drug development?","volume":"8","author":"Deng","year":"2012","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/jps.20178","article-title":"Antibody pharmacokinetics and pharmacodynamics","volume":"93","author":"Lobo","year":"2004","journal-title":"J. Pharm. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/clpt.2008.170","article-title":"Monoclonal antibody pharmacokinetics and pharmacodynamics","volume":"84","author":"Wang","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.cgh.2014.07.029","article-title":"Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab","volume":"13","author":"Yanai","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1080\/19420862.2015.1048411","article-title":"Cross-reactive and pre-existing antibodies to therapeutic antibodies\u2014Effects on treatment and immunogenicity","volume":"7","author":"Wolbink","year":"2015","journal-title":"MAbs"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fimmu.2016.00021","article-title":"Immunogenicity to Biotherapeutics\u2014The Role of Anti-drug Immune Complexes","volume":"7","author":"Krishna","year":"2016","journal-title":"Front. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1136\/annrheumdis-2015-208849","article-title":"High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: Results from the BRAGGSS cohort","volume":"76","author":"Jani","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/annrheumdis-2012-202545","article-title":"Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: A real issue, a clinical perspective","volume":"72","author":"Vincent","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/art.21671","article-title":"Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis","volume":"54","author":"Wolbink","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1080\/17425255.2017.1360280","article-title":"Biological anti-TNF drugs: Immunogenicity underlying treatment failure and adverse events","volume":"13","author":"Prado","year":"2017","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"Bartelds","year":"2011","journal-title":"JAMA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1177\/0091270007306958","article-title":"Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: Reality check","volume":"47","author":"Seitz","year":"2007","journal-title":"J. Clin. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00280-014-2445-5","article-title":"An evaluation of the potential for drug-drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma","volume":"73","author":"Darwish","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Zhou, H., and Sharma, A. (2016). Therapeutic protein-drug interactions: Plausible mechanisms and assessment strategies. Expert Opin. Drug Metab. Toxicol., 1\u20139.","DOI":"10.1080\/17425255.2016.1211109"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/ACI.0000000000000315","article-title":"An overview on safety of monoclonal antibodies","volume":"16","author":"Matucci","year":"2016","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1038\/cti.2015.14","article-title":"Clinical development methodology for infusion-related reactions with monoclonal antibodies","volume":"4","author":"Doessegger","year":"2015","journal-title":"Clin. Transl. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/ACI.0b013e3283464bcd","article-title":"Immediate adverse reactions to biologicals: From pathogenic mechanisms to prophylactic management","volume":"11","author":"Vultaggio","year":"2011","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrd3003","article-title":"The safety and side effects of monoclonal antibodies","volume":"9","author":"Hansel","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1398-9995.2009.02280.x","article-title":"Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions","volume":"65","author":"Vultaggio","year":"2010","journal-title":"Allergy"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa063842","article-title":"Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412","volume":"355","author":"Suntharalingam","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/15476910801897433","article-title":"Monoclonal antibody first dose cytokine release syndromes-mechanisms and prediction","volume":"5","author":"Wing","year":"2008","journal-title":"J. Immunotoxicol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/MPH.0000000000000485","article-title":"Rituximab-induced Cytokine Storm in the Absence of Overt Lymphoproliferative Disease","volume":"38","author":"Williams","year":"2016","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1046\/j.1365-2125.2001.00321.x","article-title":"Anti-TNF agents for rheumatoid arthritis","volume":"51","author":"Seymour","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Caminati, M., Senna, G., Stefanizzi, G., Bellamoli, R., Longhi, S., Chieco-Bianchi, F., Guarnieri, G., Tognella, S., Olivieri, M., and Micheletto, C. (2016). Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience. BMC Pulm. Med., 16.","DOI":"10.1186\/s12890-016-0290-5"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"509","DOI":"10.4155\/bio.11.2","article-title":"Unique challenges of providing bioanalytical support for biological therapeutic pharmacokinetic programs","volume":"3","author":"Nowatzke","year":"2011","journal-title":"Bioanalysis"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/FTD.0000000000000310","article-title":"Comparison of Three Assays to Quantify Infliximab, Adalimumab, and Etanercept Serum Concentrations","volume":"38","author":"Koch","year":"2016","journal-title":"Ther. Drug Monit."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20830","article-title":"Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-alpha) inhibitors [LISA-TRACKER(R) enzyme-linked immunosorbent assay (ELISA) kits, TNF-alpha-Blocker ELISA kits and Promonitor(R) ELISA kits] versus standard care in patients with Crohn\u2019s disease: Systematic reviews and economic modelling","volume":"20","author":"Freeman","year":"2016","journal-title":"Health Technol. Assess."},{"key":"ref_41","unstructured":"Chellaraj, V., Cicero, K., Abuarjah, K., Lundberg, L., Desai, H., Gadkari, S., Hantash, J., Scott, G., and Beaver, C. (2017, November 05). Comparison Between Two UV ELISA Kits and an Electrochemiluminescence ELISA Method for the Quantification of HUMIRA\u00ae (Adalimumab) in Human Serum. Available online: http:\/\/www.inventivhealthclinical.com\/497801ee-21a9-4235-91b1-2d3c9e279b38\/download.htm."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1002\/art.22214","article-title":"Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab","volume":"54","author":"Bendtzen","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1093\/rheumatology\/kem261","article-title":"Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: Assessing serum infliximab and anti-infliximab antibodies","volume":"46","author":"Svenson","year":"2007","journal-title":"Rheumatology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1136\/ard.2008.092833","article-title":"Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis","volume":"68","author":"Radstake","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_45","unstructured":"(2018, January 20). The United States Pharmacopeial Convention. Available online: https:\/\/www.google.com.hk\/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0ahUKEwiL9riFmLvZAhXMEbwKHdWOAwMQFgglMAA&url=https%3A%2F%2Fwww.ipqpubs.com%2Fwp-content%2Fuploads%2F2010%2F06%2FUSP_1032.pdf&usg=AOvVaw2leNseZklkroyS3UtgspjB."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jpba.2013.02.018","article-title":"Increased sensitivity of SPR assays in plasma through efficient parallel assay optimization","volume":"78\u201379","author":"Moberg","year":"2013","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Swanson, S., and Mytych, D. (2011). The use of Surface Plasmon Resonance for the Detection and Characterization of Antibodies. Detection and Quantification of Antibodies to Biopharmaceuticals, John Wiley & Sons.","DOI":"10.1002\/9781118075685.ch11"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2004.06.002","article-title":"Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products","volume":"289","author":"Barrett","year":"2004","journal-title":"J. Immunol. Methods"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/EBC20150001","article-title":"Introduction to biosensors","volume":"60","author":"Bhalla","year":"2016","journal-title":"Essays Biochem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1042\/EBC20150010","article-title":"Optical biosensors","volume":"60","author":"Damborsky","year":"2016","journal-title":"Essays Biochem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/3130469","article-title":"Biosensors in Health Care: The Milestones Achieved in Their Development towards Lab-on-Chip-Analysis","volume":"2016","author":"Patel","year":"2016","journal-title":"Biochem. Res. Int."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"10481","DOI":"10.3390\/s150510481","article-title":"Surface plasmon resonance: A versatile technique for biosensor applications","volume":"15","author":"Nguyen","year":"2015","journal-title":"Sensors"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.ghir.2009.04.022","article-title":"Surface plasmon resonance immunoassays\u2014A perspective","volume":"19","author":"Bosch","year":"2009","journal-title":"Growth Horm. IGF Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1365-3083.1992.tb02970.x","article-title":"Real time analysis of antibody-antigen reaction kinetics","volume":"35","author":"Malmborg","year":"1992","journal-title":"Scand. J. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jpba.2008.11.028","article-title":"The development and validation of a sensitive, dual-flow cell, SPR-based biosensor immunoassay for the detection, semi-quantitation, and characterization of antibodies to darbepoetin alfa and epoetin alfa in human serum","volume":"49","author":"Mytych","year":"2009","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-1759(03)00206-0","article-title":"Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals","volume":"278","author":"Wadhwa","year":"2003","journal-title":"J. Immunol. Methods"},{"key":"ref_57","unstructured":"Centers for Medicare & Medicaid Services (2018, February 21). Clinical Laboratory Improvement Amendments (CLIA), Available online: https:\/\/www.cms.gov\/Regulations-and-Guidance\/Legislation\/CLIA\/index.html?redirect=\/CLIA."},{"key":"ref_58","unstructured":"Van der Merwe, A. (2017, November 14). Surface Plasmon Resonance. Available online: http:\/\/www.biophysics.bioc.cam.ac.uk\/wp-content\/uploads\/2011\/02\/spr1.pdf."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/0003-2697(92)90589-Y","article-title":"Immobilization chemistries suitable for use in the BIAcore surface plasmon resonance detector","volume":"205","author":"Peck","year":"1992","journal-title":"Anal. Biochem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1039\/c2an36787d","article-title":"Antibody orientation on biosensor surfaces: A minireview","volume":"138","author":"Trilling","year":"2013","journal-title":"Analyst"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/(SICI)1099-1352(199909\/10)12:5<310::AID-JMR470>3.0.CO;2-5","article-title":"Exploring buffer space for molecular interactions","volume":"12","author":"Andersson","year":"1999","journal-title":"J. Mol. Recognit."},{"key":"ref_62","unstructured":"GE Healthcare (2017, November 15). BiacoreTM Assay Handbook. Available online: http:\/\/proteins.gelifesciences.com\/~\/media\/protein-purification-ib\/documents\/handbooks\/biacore_assay_handbook.pdf?la=en."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1021\/ac4033164","article-title":"Real-time quantification of proteins secreted by artificial connective tissue made from uni- or multidirectional collagen I scaffolds and oral mucosa fibroblasts","volume":"86","author":"Bustos","year":"2014","journal-title":"Anal. Chem."},{"key":"ref_64","unstructured":"Marquart, J.A. (2018, February 20). Surface Plasmon Resonance and Biomolecular Interaction Analysis Theory and Practice. Available online: http:\/\/www.lulu.com\/shop\/ja-marquart\/surface-plasmon-resonance-and-biomolecular-interaction-analysis\/hardcover\/product-21404460.html."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Homola, J., and Piliarik, M. (2006). Surface Plasmon Resonance (SPR) Sensors, Springer.","DOI":"10.1007\/b100321"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"25385","DOI":"10.3390\/s151025385","article-title":"Analysis of Surface Plasmon Resonance Curves with a Novel Sigmoid-Asymmetric Fitting Algorithm","volume":"15","author":"Jang","year":"2015","journal-title":"Sensors"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/0956-5663(94)80071-5","article-title":"Real-time biospecific interaction analysis","volume":"9","year":"1994","journal-title":"Biosens. Bioelectron."},{"key":"ref_68","unstructured":"Sanquin (2017, November 15). Adalimumab Level Elisa M1885. Available online: https:\/\/www.sanquin.nl\/repository\/reagentia\/ifu\/Product_flyer_Adalimumab_ELISA_kit.pdf."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jpba.2016.03.029","article-title":"Generation and characterization of a unique panel of anti-adalimumab specific antibodies and their application in therapeutic drug monitoring assays","volume":"125","author":"Bian","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1126\/science.1144603","article-title":"Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange","volume":"317","author":"Schuurman","year":"2007","journal-title":"Science"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Gizeli, E., and Lowe, C. (2002). Biomolecular Sensors, Taylor & Francis.","DOI":"10.1201\/9780203212196"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bios.2015.11.087","article-title":"Fiber optic-SPR platform for fast and sensitive infliximab detection in serum of inflammatory bowel disease patients","volume":"79","author":"Lu","year":"2016","journal-title":"Biosens. Bioelectron."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Bian, S., Lu, J., Delport, F., Vermeire, S., Spasic, D., Lammertyn, J., and Gils, A. (2017). Development and validation of an optical biosensor for rapid monitoring of adalimumab in serum of patients with Crohn\u2019s disease. Drug Test. Anal.","DOI":"10.1002\/dta.2250"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/bip.22677","article-title":"Antibody recognition in multiple sclerosis and Rett syndrome using a collection of linear and cyclic N-glucosylated antigenic probes","volume":"104","author":"Rossi","year":"2015","journal-title":"Biopolymers"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"7477","DOI":"10.1007\/s00216-015-8915-8","article-title":"Surface plasmon resonance-based methodology for anti-adalimumab antibody identification and kinetic characterization","volume":"407","author":"Cimaz","year":"2015","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/bab.1528","article-title":"Wide dynamic range of surface-plasmon-resonance-based assay for hepatitis B surface antigen antibody optimal detection in comparison with ELISA","volume":"64","author":"Tam","year":"2017","journal-title":"Biotechnol. Appl. Biochem."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1515\/cclm-2015-0987","article-title":"Therapeutic drug monitoring of infliximab: Performance evaluation of three commercial ELISA kits","volume":"54","author":"Schmitz","year":"2016","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_78","unstructured":"Sanquin (2018, January 21). Adalimumab Level ELISA. Available online: http:\/\/78.41.76.137\/antibodyshop\/datasheet\/sanquin\/M1885.pdf."}],"container-title":["Sensors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8220\/18\/3\/691\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T14:56:30Z","timestamp":1760194590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8220\/18\/3\/691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,26]]},"references-count":78,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,3]]}},"alternative-id":["s18030691"],"URL":"https:\/\/doi.org\/10.3390\/s18030691","relation":{},"ISSN":["1424-8220"],"issn-type":[{"value":"1424-8220","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,26]]}}}